Canaccord Genuity maintains MapLight Therapeutics at Buy, keeps price target at $21
Canaccord Genuity reaffirmed its Buy rating and $21 price target for MapLight Therapeutics, implying a 204.3% upside from the Nov 16 close of $6.90.
MapLight Therapeutics, Inc.
MapLight Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with central nervous system disorders. Its discovery platform uses optogenetics, single-cell transcriptomics and STARmap to identify disease-related neural circuits and drug targets. MapLight retains global development and commercial rights to its programs. Its lead candidate, ML-007C-MA, combines an M1/M4 muscarinic agonist with a peripherally acting anticholinergic and is being evaluated for schizophrenia and Alzheimer’s disease psychosis. ML-004, an immediate-release and extended-release formulation of zolmitriptan, is in development for social communication deficits and/or irritability in autism spectrum disorder. The company is also advancing preclinical programs ML-009, ML-055 and ML-021. MapLight is headquartered in Redwood City, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MPLT in the last 30 days.
See all $MPLT insider activity →Canaccord Genuity reaffirmed its Buy rating and $21 price target for MapLight Therapeutics, implying a 204.3% upside from the Nov 16 close of $6.90.
MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into A Material Definitive Agreement. On November 16, 2026, MapLight Therapeutics, Inc. (the “ Company ”) entered into a Sales Agreement (the “ Agreement ”) with Leerink Partners LLC (the “ Agent ”), pursuant to which the Company from time to time may offer and se
MapLight Therapeutics (MPLT) reported a Q3 2026 net loss of $51.6M, up from $29.4M YoY. The company plans a Phase 3 trial for ML-007C-MA in schizophrenia and continues enrollment in a Phase 2 trial for Alzheimer's disease psychosis. MPLT has $463.4M in cash and expects funds to last through 2028. The stock closed at $7.25, up 2.55%.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning MPLT (MapLight Therapeutics, Inc.). Coverage has been balanced: 2 bullish, 3 neutral, and 2 bearish.
Recent MPLT coverage spans corporate actions, insider activity and earnings.
Canaccord Genuity reaffirmed its Buy rating and $21 price target for MapLight Therapeutics, implying a 204.3% upside from the Nov 16 close of $6.90.
The ATM creates an ongoing dilution overhang risk, but also provides flexible funding capacity.
Positive trial initiation and sizable capital raise could lift the stock if data are favorable.
Strong cash position and clear trial milestones may reduce financing risk and support upside, but a $51.6M net loss adds downside pressure.
The insider sale may signal personal liquidity needs or lack of confidence, but the amount is modest.
AlphAI scores every news story that mentions MPLT with an AI model for sentiment and relevance, and aggregates insider trades from MapLight Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Canaccord Genuity reaffirmed its Buy rating and $21 price target for MapLight Therapeutics, implying a 204.3% upside from the Nov 16 close of $6.90.
MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into A Material Definitive Agreement. On November 16, 2026, MapLight Therapeutics, Inc. (the “ Company ”) entered into a Sales Agreement (the “ Agreement ”) with Leerink Partners LLC (the “ Agent ”), pursuant to which the Company from time to time may offer and se
MapLight Therapeutics (MPLT) reported a Q3 2026 net loss of $51.6M, up from $29.4M YoY. The company plans a Phase 3 trial for ML-007C-MA in schizophrenia and continues enrollment in a Phase 2 trial for Alzheimer's disease psychosis. MPLT has $463.4M in cash and expects funds to last through 2028. The stock closed at $7.25, up 2.55%.
MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in
Foff Erin Pennock (Chief Medical Officer) sold 15,355 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 ($0.12M total) on 2026-10-15.
Kroeger Christopher A. (Chief Executive Officer) sold 73,691 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 ($0.60M total) on 2026-10-15.
Catalyst4, Inc. purchased 4,400,000 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $11.38 ($50.07M total) on 2026-08-14.
MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.
MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and
MapLight Therapeutics (Nasdaq: MPLT) announced a $150 million PIPE private placement. It will sell 9,197,887 common shares at $11.38 and pre-funded warrants for up to 3,983,168 shares at $11.3799, with an exercise price of $0.0001. Proceeds will fund ML-007C-MA (VISTA Phase 2 and ZEPHYR-2 Phase 3) and working capital. Expected close Aug. 14, 2026.